Core Insights - BridgeBio Oncology Therapeutics, Inc. (BBOT) has successfully completed its business combination with Helix Acquisition Corp. II, marking a significant milestone for the company as it transitions to a public entity focused on RAS-pathway malignancies [1][3][4] Company Overview - BBOT is a clinical-stage biopharmaceutical company dedicated to developing novel small molecule therapeutics targeting RAS and PI3Kα malignancies, aiming to improve outcomes for patients with cancers driven by these prevalent oncogenes [7] Business Combination Details - The business combination was approved by Helix's shareholders on August 4, 2025, and officially closed on August 11, 2025, with Helix changing its name to BridgeBio Oncology Therapeutics, Inc. [1][2] - The combined entity is expected to have approximately $490 million in cash, cash equivalents, and marketable securities, which includes BBOT's existing cash of about $130 million and net proceeds of approximately $365 million from the business combination [3][4] Investor Support - The business combination had a relatively low redemption rate of approximately 39%, indicating strong investor confidence in BBOT's vision and pipeline [3][4] - The PIPE investment was led by Cormorant Asset Management, with participation from several prominent institutional investors, raising a total of $261 million [4][5] Pipeline and Development Focus - BBOT plans to utilize the net proceeds from the business combination to accelerate the development of its pipeline of RAS-targeted oncology drug candidates, which include BBO-8520, BBO-10203, and BBO-11818, each targeting specific cancer mutations [10][11] - The company is committed to advancing transformative therapies for patients facing deadly cancers mediated by the RAS pathway, with ongoing clinical trials for its drug candidates [3][10]